Page last updated: 2024-12-10

2,3,4-tri-o-acetylarabinopyranosyl isothiocyanate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate: RN given refers to (alpha-D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3080889
SCHEMBL ID9083711
MeSH IDM0124135

Synonyms (13)

Synonym
2,3,4-tri-o-acetylarabinopyranosyl isothiocyanate
62414-75-9
alpha-d-arabinopyranosyl isothiocyanate, 2,3,4-triacetate
[(3r,4r,5s,6s)-4,5-diacetyloxy-6-isothiocyanatooxan-3-yl] acetate
SCHEMBL9083711
boc-cck33
2,3,4-tri-o-acetyl-alpha-d-arabinopyranosyl isothiocyanate
DTXSID80211470
2,3,4-tri-o-acetyl-alpha-d-arabinopyranosyl isothiocyanate, for chiral derivatization, >=98.0%
mfcd00142781
2,3,4-tri-o-acetyl-alpha-d-arabinopyranosyl-isothiocyanate
(2s,3s,4r,5r)-2-isothiocyanatotetrahydro-2h-pyran-3,4,5-triyl triacetate
2,3,4-tri-o-acetyl- alpha -d-arabinopyranosyl isothiocyanate

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described."( A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment.
Arthur, CP; Austin, CD; Balestrini, A; Barck, KH; Bauer, RN; Bjornson, C; Bravo, DD; Brillantes, B; Carano, RAD; Chen, H; Chen, J; Chen, L; Chen, Y; Chernov-Rogan, T; Ciferri, C; Ding, HT; Doerr, J; Dourado, M; Elstrott, J; Estevez, A; Gandham, V; Gao, SS; Gogineni, A; Hackos, DH; Heredia, JE; Hötzel, K; Hu, B; Joseph, V; Jung, M; Kortmann, J; Lee, WP; Leong, L; Liederer, BM; Lin, JH; Liu, J; Liu, L; Ly, JQ; Magnuson, S; Payandeh, J; Reese, RM; Riol-Blanco, L; Rohou, A; Roose-Girma, M; Rougé, L; Safina, BS; Shields, SD; Shore, DGM; Suto, E; Tam, C; Tam, L; Vander Heiden, JA; Verma, VA; Villemure, E; Volgraf, M; Wang, J; Wang, L; Wong, RL; Wu, X; Yang, X; Zhang, J, 2021
)
0.62
" Their active therapeutic relevance was hindered by a number of factors, including instability under typical physiological conditions and low bioavailability due to low aqueous solubility."( Chemopreventive aspects, investigational anticancer applications and current perspectives on allyl isothiocyanate (AITC): a review.
Patel, JK; Patil, PB, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Oral dosing of A-967079 produces robust drug exposure in rodents, and exhibits analgesic efficacy in allyl isothiocyanate-induced nocifensive response and osteoarthritic pain in rats (ED(50): 23."( Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation.
Baker, SJ; Bianchi, BR; Chen, J; Chu, KL; DiDomenico, S; Faltynek, CR; Gauvin, DM; Han, P; Joshi, SK; Kort, ME; Kym, PR; McDonald, HA; McGaraughty, SP; Mikusa, JP; Niforatos, W; Perner, RJ; Reilly, RM; Schmidt, RG; Segreti, JA; Simler, GH; Zhang, XF; Zhong, C, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (78)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.28)18.7374
1990's0 (0.00)18.2507
2000's11 (14.10)29.6817
2010's26 (33.33)24.3611
2020's40 (51.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.49 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index5.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.56%)5.53%
Reviews1 (1.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other75 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]